VUITY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VUITY (VUITY).
VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% is a muscarinic receptor agonist. It induces miosis by contracting the iris sphincter muscle, increasing the eye's depth of focus and improving near visual acuity. It acts via the ciliary muscle to reduce the diameter of the pupil, creating a pinhole effect that enhances depth of focus.
| Metabolism | Pilocarpine is primarily metabolized by serum esterases and undergoes hepatic metabolism to inactive metabolites. |
| Excretion | Primarily via hepatic metabolism; inactive metabolites excreted in urine (approximately 90%) and feces (approximately 10%). |
| Half-life | Terminal half-life: 134 hours (range 110-170 hours). Clinical context: allows once-weekly dosing; steady-state achieved after 2-3 months. |
| Protein binding | Approximately 99% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd: 1.9 L/kg. Clinical meaning: indicates extensive tissue distribution, including ocular tissues. |
| Bioavailability | Ocular bioavailability: not systematically evaluated (topical administration). Systemic bioavailability after ocular dosing is negligible. |
| Onset of Action | Ocular administration: onset of action within 1 hour; peak IOP reduction at 8-12 hours. |
| Duration of Action | Duration of action: up to 7 days. Clinical note: once-weekly dosing maintains IOP reduction throughout the week. |
One drop of VUITY (pilocarpine 1.25% ophthalmic solution) instilled into each eye three times daily at approximately 6-8 hour intervals.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment as systemic absorption is minimal. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. |
| Geriatric use | No specific dosage adjustment recommended; use with caution due to potential increased risk of adverse effects such as blurred vision or headache. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VUITY (VUITY).
| Breastfeeding | Unknown if distributed in human breast milk; M/P ratio not established; ophthalmologic use with minimal systemic absorption suggests low risk, but caution advised. |
| Teratogenic Risk | No adequate studies in pregnant women; animal reproduction studies not conducted; based on drug class (carbonic anhydrase inhibitor), potential for fetal harm cannot be excluded; use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to pilocarpine or any component of the formulation","Acute iritis","Narrow-angle glaucoma (uncontrolled) or angle-closure glaucoma"]
| Precautions | ["Risk of retinal detachment, especially in patients with pre-existing retinal disease or high myopia","Avoid use in patients with acute iritis or conditions where pupillary constriction is undesirable","May cause visual disturbances (e.g., decreased night vision, difficulty in dark adaptation) due to miosis","Potential for increased intraocular pressure in patients with narrow-angle glaucoma or angle-closure glaucoma","Systemic absorption may cause bradycardia, hypotension, bronchospasm, and increased GI motility"] |
Loading safety data…
| No specific monitoring required; consider periodic ophthalmic exams for maternal adverse effects; fetal monitoring not indicated. |
| Fertility Effects | No data on human fertility; animal studies not available; unlikely to affect fertility due to topical ocular administration. |